Jason Mohr, DO
Pulmonary Disease · West Des Moines, IANPI 1801909379
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $145 of the $178 with a category attached, or 81.4%. 4 manufacturers reported payments, led by Intuitive Surgical at 54.9% of the total. 2023 is the largest year on record at $98, 6.6 times the $15 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in IA, where the typical reported total is $578.
Across 4 payments — averaging $44.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$98
- KARL Storz Endoscopy-america$47
- United Therapeutics Corporation$18
- Boehringer Ingelheim$15
Across 1 payment — averaging $37,326 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$37K
What the payments were for
- Food & beverage$14581%
- Education$3319%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $98 |
| KARL Storz Endoscopy-america | 1 | $47 |
| United Therapeutics Corporation | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$178 in reported general payments places this provider in the 35th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 388 | $321,816 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 32 | $299,841 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $198,048 |
| Breo ElliptaFluticasone/Vilanterol | 453 | $197,742 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 288 | $133,907 |
| Spiriva HandihalerTiotropium Bromide | 31 | $27,485 |
| DuleraMometasone/Formoterol | 71 | $25,699 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $21,619 |
| Spiriva RespimatTiotropium Bromide | 36 | $18,093 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $17,803 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $16,950 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,947 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 59 | $8,334 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $7,921 |
| Bosentan | 12 | $7,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $15 | $39,71281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in West Des Moines
- Dustin McCannWest Des Moines$67K
- Matthew TrumpWest Des Moines$41K
- James MallenWest Des Moines$16K
- Samantha Danielson-JonesWest Des Moines$11K
- Ryan BrimeyerWest Des Moines$9K
- Amerlon EnriquezWest Des Moines$7K
- Daniel DodgeWest Des Moines$6K
- Ryan MertensWest Des Moines$6K
- John ScottWest Des Moines$3K
- Katrina GuestWest Des Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.